Accelerated Synthesis of Novel Indole-3-Sulfonamides Leveraging High-Throughput Experimentation
Abstract Non-nucleoside reverse transcriptase inhibitors are key compounds of current antiretroviral therapy for people living with human immunodeficiency virus (HIV). Indole-3-sulfonamides have demonstrated good biological profile against HIV. Here we describe a high-throughput experimentation (HTE)-compatible route to access indole-3-sulfonamides through a selective activation of the S–N bond of a primary indole-3-sulfonamide. This selective activation strategy enables efficient installation of diverse amine substituents with broad functional-group tolerance. Cheminformatic tools were integrated into the workflow to analyze accessible chemical space, prioritize amine nucleophiles, and guide building-block selection to maximize structural diversity. The protocol rapidly delivered a set of novel indole-3-sulfonamide analogs, demonstrating practical applicability and efficiency for medicinal chemistry campaigns.
Authors
- Olivia P. Bercher (ORCID: https://orcid.org/0000-0002-0000-3688)
- Abdellatif El Marrouni (ORCID: https://orcid.org/0000-0001-5408-0374)
- Michael J. Breslin
- Kaitlin Lupinacci
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-08-18
- DOI
- https://doi.org/10.1021/acsmedchemlett.6c00331
- Primary Topic
- Synthesis and Catalytic Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00